bifico

Phase 1Small molecule

TTongji Hospital

bifico is one of 93 small molecule programs targeting Colitis. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

ColitisActive, not recruiting

Cognitive ImpairmentActive, not recruiting

Hepatocellular CarcinomaActive, not recruiting

ColitisPhase 1

Active, not recruiting

Cognitive ImpairmentPreclinical

Active, not recruiting

Hepatocellular CarcinomaPreclinical

Active, not recruiting

Competition

Competitive Landscape

797 competitors in Hepatocellular Carcinoma

#DrugCompanyPhaseTrials

Ibrance

Pfizer

Preclinical

1 2

Viread

Gilead

Preclinical

1 3

Cysteine Hydrochloride

Novartis

Preclinical

1 4

Sovaldi

Gilead

Preclinical

1 5

Hepsera

Coreg

2 7

Apatinib

LLaNova Medicines Zhejiang Co., Ltd.

Preclinical

16 8

Doptelet

AAkarx

Preclinical

1 9

Opdivo

Bristol-Myers Squibb

Preclinical

2 10

PD-1 Inhibitor

Johnson & Johnson

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Advanced NSCLC1 trial

Probiotics Combined With Chemotherapy for Patients With Advanced NSCLC

Unknown status·SShanghai 10th People's Hospital·Phase 3·NCT03642548·180 enrolled

Hepatocellular Carcinoma1 trial

Clinical Study on BIFICO Accelerating Postoperative Liver Function Recovery in Patients With Hepatocellular Carcinoma

Completed·TTongji Hospital·N/A·NCT05178524·180 enrolled

Cognitive impairment1 trial

A 12-weeks Study to Evaluate the Dietary Fiber and Probiotics Treatment in Prevention and Intervention of Weight-gain and Cognitive Impairment of Schizophrenia or Bipolar Disorder

Completed·—·N/A·NCT03379597·136 enrolled

Colitis1 trial

A Trial on Probiotics in Preventing Hirschsprung's Disease Associated Entercolitis

Completed·TTongji Hospital·Phase 1·NCT01934959·60 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for bifico. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — bifico compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for bifico. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Tongji Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: TTongji Hospital

bifico

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Advanced NSCLC1 trial

Hepatocellular Carcinoma1 trial

Cognitive impairment1 trial

Colitis1 trial

References

Drug Info

Quick Facts

Related News